Home > Investors
2017 News and Events
E-mail Page Print Page RSS Feeds E-mail Alerts IR Contacts Financial Tear Sheet 
About Us
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
11/29/17The Medicines Company Announces Definitive Agreement to Sell its Infectious Disease Business Unit to Melinta Therapeutics
—Transaction will significantly strengthen the Company’s financial position; expected to provide sufficient cash and liquidity to advance inclisiran through anticipated completion of pivotal trials and data readout in second half of 2019— —Transaction structure will provide potential to create additional value through robust royalty structure on future sales of antibiotic portfolio and ownership of Melinta common stock— PARSIPPANY, N.J... 
Printer Friendly Version
11/15/17The Medicines Company Names Dr. Fred Eshelman as Executive Chairman; Appoints Geno Germano to Its Board of Directors
PARSIPPANY, N.J.--(BUSINESS WIRE)--Nov. 15, 2017-- The Medicines Company (NASDAQ:MDCO) today announced that its Board of Directors has appointed Fredric N. Eshelman, PharmD., the Company’s current Chairman of the Board, to the newly created position of Executive Chairman, and Geno Germano, a pharmaceutical industry executive with over 30 years of leadership experience, as a new, independent Director of the Company. These appointments are effective ... 
Printer Friendly Version
11/06/17The Medicines Company and Alnylam Pharmaceuticals Announce Initiation of Phase III Clinical Trials of Inclisiran
– Patient dosing commenced – – Comprehensive Phase III clinical program to assess LDL-C lowering and safety in a wide range of patients – – Efficient, focused and rapid program designed to support US and EU regulatory filings – PARSIPPANY, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 6, 2017-- The Medicines Company (NASDAQ: MDCO) and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) today announced the initiation of the Phase ... 
Printer Friendly Version
10/25/17The Medicines Company Reports Third-Quarter 2017 Business and Financial Results
PARSIPPANY, N.J.--(BUSINESS WIRE)--Oct. 25, 2017-- The Medicines Company (NASDAQ: MDCO) today reported its financial results for the third quarter ended September 30, 2017, and provided an update on its clinical and operational activities. “We made significant clinical and strategic progress during the third quarter,” said Clive Meanwell, M.D., Ph.D., Chief Executive Officer of The Medicines Company. “We aggressively advanced start-up work for th... 
Printer Friendly Version
10/20/17The Medicines Company to Announce Third-Quarter 2017 Financial Results on October 25
PARSIPPANY, N.J.--(BUSINESS WIRE)--Oct. 20, 2017-- The Medicines Company (NASDAQ:MDCO) will host a conference call on Wednesday, October 25, 2017, at 8:30 a.m., Eastern Time, to discuss its third-quarter 2017 financial results and operational developments. A live audio webcast of the conference call may be accessed in the Investors section of The Medicines Company website. A replay of the webcast will be available on the website fol... 
Printer Friendly Version
10/05/17The Medicines Company to Present New Data from TANGO II Study of VABOMERE™ (meropenem and vaborbactam) at IDWeek 2017
–VABOMERE was associated with higher overall cure and lower mortality versus “best available therapy” in subjects with known or suspected carbapenem-resistant Enterobacteriaceae (CRE)– –VABOMERE was also associated with better safety and significantly better overall risk-benefit than best available therapy– PARSIPPANY, N.J.--(BUSINESS WIRE)--Oct. 5, 2017-- The Medicines Company (NASDAQ:MDCO) today announced that new data from it... 
Printer Friendly Version
09/28/17The Medicines Company to Present Data at IDWeek 2017 on Infectious Disease Portfolio Including Recently Approved Antibiotic VABOMERE™ (meropenem and vaborbactam)
– Eight posters presented on Friday and Saturday highlight comprehensive results of TANGO-2, a multi-center, randomized, open label clinical trial of VABOMERE vs. "best available therapy" in subjects with known or suspected CRE – – VABOMERE was recently approved for the treatment of adult patients with complicated urinary tract infections, including pyelonephritis, caused by designated susceptible Enterobacteriacea – PARSIPPANY, N.J.--(B... 
Printer Friendly Version
08/30/17The Medicines Company Announces FDA Approval of VABOMERE™ (meropenem and vaborbactam)
–Accelerated approval for the treatment of adult patients with complicated urinary tract infections, including pyelonephritis– –First carbapenem-based combination product – combination of meropenem with a new class of beta-lactamase inhibitor– –Addresses pathogens designated by the CDC as urgent and serious antimicrobial resistance threats, and pathogens cited by the WHO as a critical need for new antibiotics– –VABOMERE exp... 
Printer Friendly Version
08/28/17New, One-Year Data from ORION-1 Phase II Study of Inclisiran Extends Excellent Long-Term Efficacy and Safety Profile, Affirming Dose for Phase III Trials
–Inclisiran lowering effects on bad-cholesterol (LDL-C) are robust (mean 56% at Day-150; maximum 81%) and sustained (average 51% across a planned six-month dosing interval), with minimum intra-patient variability– –Safety data for inclisiran from ORION-1 now include 370 subject-years of observation, including at least 300 subject-years of inclisiran effects; no material safety issues observed on inclisiran – similar to placebo– ... 
Printer Friendly Version
08/09/17The Medicines Company Reports Second Quarter 2017 Business and Financial Results
PARSIPPANY, N.J.--(BUSINESS WIRE)--Aug. 9, 2017-- The Medicines Company (NASDAQ:MDCO) today reported its financial results for the second quarter ended June 30, 2017, and provided an update on its clinical and operational activities. Second Quarter 2017 Highlights and Projected Milestones Meropenem-Vaborbactam The Company announced positive results from a planned, interim analysis of the TANGO-2 trial of its fix... 
Printer Friendly Version
07/31/17The Medicines Company to Announce Second-Quarter 2017 Financial Results on August 9
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 31, 2017-- The Medicines Company (NASDAQ:MDCO) will host a conference call on Wednesday, August 9, 2017, at 8:30 a.m., Eastern Daylight Time, to discuss its second-quarter 2017 financial results and operational developments. A live audio webcast of the conference call may be accessed in the Investors section of The Medicines Company website. A replay of the webcast will be available on the web... 
Printer Friendly Version
07/25/17The Medicines Company announces TANGO-2 trial of meropenem-vaborbactam (formerly, Carbavance) stopped early for superior benefit-risk compared to best available therapy for CRE
—Trial stopped early following recommendation by independent Data Safety and Monitoring Board— —Meropenem-vaborbactam demonstrated improved clinical cure rates across all infection types and reduced rate of renal adverse events compared to best available therapy— —The Company also announces VabomereTM as the U.S. and European trade name for meropenem-vaborbactam— PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 25, 2017-- The Med... 
Printer Friendly Version
05/30/17The Medicines Company to Present Data at ASM Microbe 2017 on Infectious Disease Portfolio Including Late-Stage Investigational Antibiotic Meropenem-Vaborbactam
PARSIPPANY, N.J.--(BUSINESS WIRE)--May 30, 2017-- The Medicines Company (NASDAQ:MDCO) today announced that data from its portfolio of antimicrobial products and late-stage product candidates will be featured in presentations at the American Society for Microbiology’s ASM Microbe 2017 to be held June 1-5, 2017 in New Orleans. The Medicines Company’s infectious disease research and product development is focused on the most serious multi-drug resist... 
Printer Friendly Version
05/04/17The Medicines Company to Participate in the Bank of America Merrill Lynch 2017 Health Care Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--May 4, 2017-- The Medicines Company (NASDAQ:MDCO) today announced that it will participate in the Bank of America Merrill Lynch 2017 Health Care Conference on Tuesday, May 16, 2017, in Las Vegas, Nevada. Clive Meanwell, M.D., Ph.D., Chief Executive Officer, will participate in a fireside chat at 8:00 a.m., Pacific Daylight Time. A live audio webcast will be available in the “Investors-Events/Presentations... 
Printer Friendly Version
04/26/17The Medicines Company Reports First-Quarter 2017 Financial Results
PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 26, 2017-- The Medicines Company (NASDAQ:MDCO) today announced its business and financial results for the first-quarter ended March 31, 2017. “During the first quarter of 2017, The Medicine Company continued to deliver excellent execution against our 2017 objectives, significantly advancing key development programs, strictly managing cash deployment to enhance our ability to support our products and pipelin... 
Printer Friendly Version
04/26/17The Medicines Company and Alnylam Pharmaceuticals Announce Agreement with FDA on Phase III Clinical Program for Inclisiran
— Pivotal trials will enroll approximately 1,500 subjects randomized to inclisiran versus approximately 1,500 subjects randomized to placebo, with a primary endpoint of LDL-C and an 18-month study period — — NDA submission anticipated at or around the end of 2019 — PARSIPPANY, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 26, 2017-- The Medicines Company (NASDAQ:MDCO) and Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) today announced that T... 
Printer Friendly Version
04/17/17The Medicines Company to Present Data at ECCMID 2017 on Infectious Disease Portfolio Including Investigational Antibiotic Meropenem-Vaborbactam
PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 17, 2017-- The Medicines Company (NASDAQ:MDCO) today announced that data from its portfolio of antimicrobial products and late-stage product candidates will be featured in presentations at the 27th Annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2017) to be held April 22-25, 2017, in Vienna, Austria. The Company will present data on its investigational antibiotic, ... 
Printer Friendly Version
04/12/17The Medicines Company to Announce First-Quarter 2017 Financial Results on April 26, 2017
PARSIPPANY, N.J.--(BUSINESS WIRE)--Apr. 12, 2017-- The Medicines Company (NASDAQ:MDCO) will host a conference call on Wednesday, April 26, 2017, at 8:30 a.m., Eastern Daylight Time, to discuss first-quarter 2017 financial results and operational developments. The dial-in information to access the call is listed below: U.S./Canada: (877) 359-9508 International: (224) 357-2393 Conference ID: 4094876 A taped replay of... 
Printer Friendly Version
03/31/17The Medicines Company Appoints Paris Panayiotopoulos to Its Board of Directors
PARSIPPANY, N.J.--(BUSINESS WIRE)--Mar. 31, 2017-- The Medicines Company (NASDAQ:MDCO) today announced that it has appointed Paris Panayiotopoulos to its Board of Directors. Mr. Panayiotopoulos, who will serve as a Class I director, will stand for election at the Company’s 2017 Annual Meeting of Stockholders. With the appointment of Mr. Panayiotopoulos, the Company’s Board of Directors comprises 11 directors, 10 of whom are independent and three of whom ... 
Printer Friendly Version
03/30/17The Medicines Company to Present at Needham Healthcare Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--Mar. 30, 2017-- The Medicines Company (NASDAQ:MDCO) today announced that it will present at the 16th Annual Needham Healthcare Conference on Tuesday, April 4, 2017, at 8:00 a.m., Eastern daylight time. The live webcast may be accessed in the “Investors-Events/Presentations” section of The Medicines Company website. A replay of the presentation will be available. About The Medicines Company ... 
Printer Friendly Version
03/17/17The Medicines Company and Alnylam Pharmaceuticals Report Positive Final Results from ORION-1 Phase II Study of Inclisiran
—Inclisiran demonstrated significant and sustained reductions in LDL-C and high standards of safety and tolerability— —Optimal starting dose regimen (300 mg injection administered on Day-1 and Day-90) lowered LDL-C by average of 52.6% (64 mg/dL) and up to 81% (122 mg/dL) at Day-180, and by time-adjusted mean of >50% (63 mg/dL) for the six-month period from Day-90 through Day-270; every patient displayed significant response and mean LDL-C redu... 
Printer Friendly Version
03/14/17The Medicines Company to Webcast Presentation of ORION-1 Phase II Study of Inclisiran at ACC.17
Late-breaking session featuring data from ORION-1 study to be webcast simultaneously with presentation at 1:30 p.m. on March 17, 2017 New Time for Conference Call – Previously-scheduled conference call/webcast to review data from ORION-1 moved to 4:30 p.m. on March 17, 2017 PARSIPPANY, N.J.--(BUSINESS WIRE)--Mar. 14, 2017-- The Medicines Company (NASDAQ: MDCO) today announced that it will webcast, over the internet simultaneousl... 
Printer Friendly Version
03/06/17The Medicines Company to Host Conference Call and Webcast at Upcoming American College of Cardiology’s 66th Annual Scientific Sessions
– Late-breaking data from ORION-1 Phase II study of inclisiran (PCSK9si) will be reviewed by the Company and members of its distinguished advisory board – PARSIPPANY, N.J.--(BUSINESS WIRE)--Mar. 6, 2017-- The Medicines Company (NASDAQ:MDCO) will host a conference call and webcast on Friday, March 17, 2017, at 3:30 p.m., Eastern Time, to review data from the ORION-1 Phase II study of inclisiran, the Company’s PCSK9 synthesis inhibitor. D... 
Printer Friendly Version
02/28/17The Medicines Company Reports Fourth-Quarter and Full-Year 2016 Financial Results
PARSIPPANY, N.J.--(BUSINESS WIRE)--Feb. 28, 2017-- The Medicines Company (NASDAQ:MDCO) today announced its financial results for the fourth-quarter and full-year ended December 31, 2016. “Driven by strong execution against our strategic priorities, 2016 was a transformative year for the Company,” said Clive Meanwell, M.D., Ph.D., Chief Executive Officer of The Medicines Company. “We announced positive top-line results from the ORION-1 Phas... 
Printer Friendly Version
02/21/17The Medicines Company Announces FDA Filing Acceptance of New Drug Application for Intravenous Antibiotic Carbavance® (meropenem-vaborbactam)
PARSIPPANY, N.J.--(BUSINESS WIRE)--Feb. 21, 2017-- The Medicines Company (NASDAQ:MDCO) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Company’s new drug application (NDA) filing for Carbavance® (meropenem-vaborbactam) for the treatment of complicated urinary tract infections (cUTIs). The FDA does not currently plan to hold an advisory committee meeting to discuss the application. ... 
Printer Friendly Version
02/17/17The Medicines Company to Announce Fourth-Quarter and Full-Year 2016 Financial Results on February 28, 2017
PARSIPPANY, N.J.--(BUSINESS WIRE)--Feb. 17, 2017-- The Medicines Company (NASDAQ:MDCO) will host a conference call on Tuesday, February 28, 2017, at 8:30 a.m., Eastern Time, to discuss fourth-quarter and full-year 2016 financial results and operational developments. The dial-in information to access the call is listed below: U.S./Canada: (877) 359-9508 International: (224) 357-2393 Conference ID: 66296847 A taped r... 
Printer Friendly Version
01/25/17The Medicines Company to Present Results from ORION-1 Phase 2 Study of Inclisiran at the American College of Cardiology’s 66th Annual Scientific Session
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jan. 25, 2017-- The Medicines Company (Nasdaq: MDCO) today announced that full safety and efficacy data from the ORION-1 Phase 2 study of inclisiran, with six- to nine-month follow-up for all patients in the study, will be presented at the American College of Cardiology's 66th Annual Scientific Session (ACC.17), to be held March 17-19, 2017, in Washington D.C. The ORION-1 study will be presented in the “Late-Breaking Cl... 
Printer Friendly Version
01/08/17The Medicines Company Announces Positive Top-Line Results from Day 180 Interim Analysis in Ongoing ORION-1 Phase 2 Study of Inclisiran (formerly, PCSK9si)
Compelling safety and efficacy data from Day 180 interim analysis Inclisiran continued to demonstrate significant and durable LDL-C reduction, reaffirming the potential for a highly-differentiated dosing regimen of two or three injections per year Inclisiran continued to demonstrate high standards of safety and tolerability The Medicines Company reinforces its commitment to advancing the development of inclisiran with initi... 
Printer Friendly Version
01/04/17The Medicines Company to Present at J. P. Morgan Healthcare Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jan. 4, 2017-- The Medicines Company (Nasdaq: MDCO) today announced that its Chief Executive Officer, Clive Meanwell, M.D., Ph.D., will present at the 35th Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2017, at 7:30 a.m., Pacific time. A live audio webcast of the presentation will be available in the “Investors” section of The Medicines Company website, www.themedicinescompany.com, ... 
Printer Friendly Version